Our human Stem-SPACE™ technology platform leverages discovery of functionally discrete single cells and precise control over the development process from lab-grown stem cells.
Focusing on cell type doesn’t capture rare cell types that affect desired potency.
Unhealthy autologous donor cells create high variability in quality of raw source material.
Lower rate of cell expansion / differentiation creates less manufacturing yield at high costs.
The technology platform harnesses the incredible potential of healthy umbilical cord derived blood stem cells as a starting material to expand and manufacture potent stem cells for clinical use.
The technology platform achieves controlled and well-characterized differentiation process by mimicking developmental process of blood formation in a dish to produce a broad arsenal of rare immune cell types.
Vishwakarma et al, Nature Communications Biology (2021)
"At Cell BioEngines, we leverage the natural biology of cells for large scale manufacturing. Each cord unit allows 10-100’s of doses (many patients) per manufacturing run providing unparalleled scalability" - Founder & CEO